[Sevelamer:hydrochloride]
Toru Hyodo1, Takayasu Taira, Haruki Wakai
1Kidney Center, Yokohama Daiichi Hospital, Department of Urology, Kitasato University School of Medicine, Japan.
Insights
Sevelamer hydrochloride inhibits coronary artery calcification progression in renal osteodystrophy patients. Strategies to manage constipation improved patient adherence, crucial for preventing calcification and improving survival.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Renal osteodystrophy is linked to coronary artery calcification (CAC) progression.
- CAC is a significant risk factor for mortality in non-hemodialysis patients.
- Sevelamer hydrochloride demonstrates inhibitory effects on CAC progression.
Purpose of the Study:
- To investigate strategies for improving sevelamer hydrochloride adherence in Japanese patients.
- To overcome the challenge of constipation, a common side effect limiting sevelamer hydrochloride use.
- To enhance CAC prevention and long-term survival in patients with renal osteodystrophy.
Main Methods:
- Patient education on the low incidence of CAC with sevelamer hydrochloride.
- Co-administration of sorbitol, an osmotic purgative, to mitigate constipation.
- Gradual replacement of calcium carbonate with sevelamer hydrochloride, starting with evening doses.
Main Results:
- The implemented protocol significantly increased sevelamer hydrochloride intake.
- An 86.7% patient adherence rate was achieved with the modified administration strategy.
- This approach facilitates better management of CAC in renal osteodystrophy.
Conclusions:
- Improving sevelamer hydrochloride intake is vital for preventing coronary artery calcification.
- Effective management of side effects like constipation can enhance patient adherence.
- Increased adherence to sevelamer hydrochloride contributes to improved long-term survival.
Abstract:
The recent global breakthrough in the field of renal osteodystrophy is the inhibitory effect of sevelamer hydrochloride on the progression of coronary artery calcification, which was revealed with EBCT (Electron beam computed tomography) 1) approximately 3). It has been found that the degree of coronary artery calcification assessed with EBCT is proportional to the mortality risk by the coronary artery stenosis and by myocardial infarction in non-hemodialysis patients 4) approximately 10). In 2004 in Japan Matsuoka and Iseki et al showed for the first time in the world that coronary artery calcification assessed by EBCT was correlated with mortality 11). In Japan, however, it is difficult to administer sevelamer hydrochloride to many patients because of constipation as its side effect. Its prescription rate is 26.8% and its single administration rate is only 15.4% 12). We explained fully to the patients that sevelamer hydrochloride seldom caused coronary artery calcification. And we used sorbitol, an osmotic purgatives, with sevelamer hydrochloride. Moreover, we gradually replaced calcium carbonate with sevelamer hydrochloride in supper at first. With protocol above, we succeeded in having 86.7% of the patients take sevelamer hydrochloride 12). We think that it is important to increase the intake rate of sevelamer hydrochloride in order to prevent coronary artery calcification and to aim at the long survival of the patients.
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Antihypertensive Drugs: Thiazide-Class Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Antihypertensive Drugs: Potassium-Sparing Diuretics
Renal Drug Excretion: Tubular Secretion

